Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus INDERIDE 80 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus INDERIDE 80 25.
ENDURONYL FORTE vs INDERIDE-80/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Beta Blocker and Thiazide Diuretic